This suggests that not only NGFR and Ecad but additional correlating genes may underlay cellular plasticity-related regulation of expression, hence therapeutic targeting of the MET receptor signaling pathway by small molecule inhibitors may eliminate several MET+ tumor cell subsets. The gene discussed is NGFR; the disease is neoplasm.